Congratulations to Olive Sturtevant, MHP, MT(ASCP), SBB, SLS, ASQ (CQA), of our Connell and O'Reilly Families Cell Manipulation Core Facility and recipient of the AABB's 2025 President's Award for her extraordinary dedication and service.

New research published in @natchembio.nature.com by @danafarber.bsky.social’s William Gibson, MD, PhD, reveals a general strategy for TP53 missense mutant cancers (majority) with prototype small molecules. @broadinstitute.org Read more at bit.ly/4onnFJO

The @fda.gov approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloid leukemia (AML) with NPM1 gene mutations. Learn more: bit.ly/3WEexnN

What happens when targeted therapy meets radiation therapy? Learn about the exciting and innovative form of medicine called radioligand therapy: bit.ly/47vXrxy

Dr. Vinayak Venkataraman of @danafarber.bsky.social spoke with @curetoday.bsky.social about how emerging second- and third-line therapeutic strategies and investigational agents may shift the standard of care for patients with GIST. ➡️ bit.ly/3LI7yry

In a study published in the Journal of Pediatric Psychology, Eric Zhou, PhD, highlights Dana-Farber/Boston Children's Cancer and Blood Disorders Center's new "Sleep ALL Night" program, which aims to help children with leukemia sleep better during treatment. Read more: bit.ly/47NOhO0

Back in 2014, there were no targeted therapies approved for childhood brain cancers. Now there are a few, with more on the radar – almost all of which have deep roots in our science. Learn more about how our research is advancing treatment for childhood brain cancer: bit.ly/47hUQZd

Please join us for a webinar on What to Know About Lung Cancer. Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA

Sara Tolaney, MD, of @danafarber.bsky.social publishes data from DESTINY Breast09 in @nejm.org showing T-DXd plus pertuzumab significantly prolonged progression-free survival compared to standard treatment in first-line therapy for metastatic HER2+ breast cancer. ➡️ bit.ly/3JxnaO5

Congratulations to Dr. Chris Lathan of @danafarber.bsky.social, recipient of the Randolph W. “Bill” Bromery Legacy Award from @umassamherst.bsky.social for his deep commitment to social justice, diversity, equity, and inclusion. ➡️ bit.ly/4qvbFao 📷 Stephanie Berenson Photography

We're proud to be included in Becker's 100 hospitals and health systems with great oncology programs 2025 list. Learn more and view the full list here: bit.ly/3Wn6yvj

New research in @natgenet.nature.com from @danafarber.bsky.social’s @ckadoch.bsky.social and Jessica St. Laurent, MD, uncovers potential targeted therapy for endometrial cancer. bit.ly/3Jq2Yxv

Gene therapy works by replacing or disabling faulty genes. Immunotherapy helps the immune system recognize and attack cancer cells. Discover how these two powerful approaches work together: bit.ly/48ZL92B

In a ‘Challenge your Expert’ session, Paula Ugalde, MD, discusses how highly effective neoadjuvant therapies are reshaping the definition of lung cancer resectability, offering new treatment possibilities for patients. #ESMO25

Erica Mayer, MD, MPH, delivers patient-reported data supporting SERENA-6 treatment approach to optimize outcomes and improve quality of life for patients with advanced breast cancer. #ESMO25

Thomas Hwang, MD, explores the magnitude of clinical benefits of cancer medicines in curative settings and the assessment of health decisions across Europe. #ESMO25

We’re back for day four of #ESMO25. Follow along here and with @danafarbernews.bsky.social as continue to learn and explore the latest in oncology care and research: bit.ly/478Z1qh

Erica Mayer, MD, MPH, highlights evolving endocrine treatment strategies for HR-positive breast cancer and how front-line advances are moving into earlier stages of care on panel with @drsarahsammons.bsky.social. #ESMO25

Filipa Lynce, MD, shares insights on tailoring breast cancer care for special populations, highlighting strategies to ensure personalized and equitable treatment for all patients. #ESMO25

Filipa Lynce, MD, shares insights on tailoring breast cancer care for special populations, highlighting strategies to ensure personalized and equitable treatment for all patients. #ESMO25

@drchoueiri.bsky.social co-chairs today’s Presidential Symposium, welcoming the estimated 9,000 people in the room. #ESMO25

Joaquim Bellmunt, MD, PhD, highlights the mechanism of action, efficacy, and safety profile of antibody-drug conjugates in bladder cancer. #ESMO25

Alicia Morgans, MD, MPH, moderates a discussion on advancing personalized care for prostate cancer, exploring patient-centered solutions for metastatic hormone-sensitive and non-metastatic castration-resistant prostate cancer. #ESMO25

Catherine Wu, MD, gives a keynote address on the future of therapeutic cancer vaccines from a clinical perspective. #ESMO25

Erica Pimenta, MD, PhD, explores opportunities for how GLP-1 based medicines – commonly used for diabetes and weight management – could play a role in cancer prevention and treatment. #ESMO25

@guinadermarta.bsky.social takes part in the ESMO Resilience Task Force Open Forum, highlighting strategies to co-create a resilient oncology workforce and support clinician well-being. #ESMO25

Paul Nguyen, MD, MBA, presents results from the ENZARAD trial – examining whether adding enzalutamide to standard hormone + radiation therapy can improve outcomes for people with high-risk prostate cancer. #ESMO25

Based on results from three clinical trials, Marc Machaalani, MD, shares new findings of how MAdCAM-1 helps predict outcomes for people with metastatic renal cell carcinoma. #ESMO25

@ptarantinomd.bsky.social explores safety optimization of the next frontier of antibody-drug conjugate development. #ESMO25

Wenxin (Vincent) Xu, MD, shares new insights from COSMIC-313 which explores how a blood maker KIM-1 may help predict outcomes for patients with advanced kidney cancer. #ESMO25

We’re back today at #ESMO25. Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in oncology care and research or join us at our upcoming discussions and poster presentations: bit.ly/478Z1qh

Julia Rotow, MD, shares strategies to overcome resistance in EGFR-mutated NSCLC, focusing on treatment approaches after disease progression to advance care for patients with lung cancer. #ESMO25

@stolaney1.bsky.social addresses a full house during the #ESMO25 presidential discussion on Reshaping Density – Transforming Outcomes in High-Risk HER2+ Breast Cancer.

The first day of poster presentations at #ESMO25 featured some of our expert's insights into topics from the impact of genomic alterations to results from a phase Ill trial of immunotherapy responders.

Robert Haddad, MD, and Ravindra Uppaluri, MD, PhD, join an interactive case discussion on state-of-the-art management of resectable locally advanced head and neck cancer, exploring how novel strategies are being integrated into patient care. #ESMO25

@stolaney1.bsky.social shares an emerging role of antibody-drug conjugates in first-line treatment of metastatic triple-negative breast cancer, highlighting new possibilities for earlier use of these therapies. #ESMO25

Pasi A. Jänne, MD, MPH, is back on stage sharing advancing targeted therapy research for patients with KRAS G12C-mutated NSCLC, highlighting emerging strategies and growing momentum in lung cancer treatment. #ESMO25

Pasi A. Jänne, MD, MPH discussing strategies to target oncogenes in NSCLC, with a focus on preventing and treating resistance to improve outcomes for patients with lung cancer. #ESMO25

Erica Mayer, MD, MPH, presents the first results from a evERA BC trial which studies a new oral therapy, giredestrant, combined with everolimus for people with advanced ER+/HER2– breast cancer who have already tried CDK4/6 treatments. #ESMO25

#ESMO25 continues today! Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in oncology care and research or join us at our upcoming discussions and poster presentations: bit.ly/4nfWCyL

@stolaney1.bsky.social joins the #ESMO25 roundtable with other leading oncology experts for a dynamic session on strategic sequencing in HER2+ metastatic breast cancer.

Lung cancer research at #ESMO25: Chemotherapy combo boosts overall survival in patients with EGFR-mutant non-small cell lung cancer. @danafarber.bsky.social's Dr. Pasi Jänne presents the complete data from phase 3 FLAURA2 study. Press release ➡️bit.ly/47oV0hd

Pasi A. Jänne, MD, MPH, presents exploratory results from the FLAURA2 study, examining outcomes for patients with advanced EGFR-mutated lung cancer treated with osimertinib, with or without chemotherapy, as first-line therapy. #ESMO25

We’re excited to be at #ESMO25! Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in oncology care and research or join us at our upcoming discussions and poster presentations: bit.ly/4nfWCyL

Congratulations to Paul Richardson, MD, recognized by the Lymphoma, Leukemia, & Myeloma Congress with the Joseph Michaeli Award for Outstanding Contributions to Myeloma. His leadership helped introduce cornerstone treatments for multiple myeloma, each of which has kept the field at the cutting edge.

Join us in congratulating Jessica A. Pollard, MD, on receiving the 2025 Healing Hero of Excellence in Pediatric Oncology award from Kids Beating Cancer, recognizing her compassionate care and dedication to advancing childhood cancer cures.

Can chemotherapy and immunotherapy work better together? For some cancers, the answer is yes. Research has shown that combining these treatments, called chemoimmunotherapy, can lead to better outcomes than either treatment alone. Learn how these therapies work together: bit.ly/3HcPYdF

Breast cancer patients who participated in a weight loss intervention program lost an average of 4.7% of their baseline body weight after one year, while those in the education only control group gained an average 1% of their baseline weight. Learn more about the findings: bit.ly/3Kpesld

Sara Tolaney, MD, of @danafarber.bsky.social joined @boston25news.com to discuss the latest in breast cancer treatment, trends and screening. ➡️ bit.ly/3WvxUze

Congratulations to Philip J. Kranzusch, Ph.D., Professor of Cancer Immunology and Virology, who was one of three scientists awarded top honors at the 2025 Blavatnik National Awards for Young Scientists. Watch to learn more about his work: bit.ly/4pZUDkF